Minoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...
Read more
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2...
Read more
With remote patient monitoring of blood pressure through Babyscripts myBloodPressure, MemorialCare providers align with industry guidance from the American College of Obstetricians and Gynecologists (...
Read more
Mineralys Therapeutics today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN...
Read moreSparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, shares progress in its lead gene therapy program, SPVN06, and research on retinitis pi...
Read more
Minoryx Therapeutics today announces 24-week interim results from NEXUS. This open label registration-enabling clinical trial is assessing the safety and efficacy of lead candidate leriglitazone, a no...
Read more
Kala Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) fo...
Read more
Kala Pharmaceuticals today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal s...
Read more
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced fi...
Read more
AM-Pharma B.V. today announced that Professor Peter Pickkers, M.D., Ph.D., principal investigator of the Phase 3 REVIVAL study, will present data from the study at two upcoming scientific conferences....
Read more
The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) ago...
Read more
NorthSea Therapeutics today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic st...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The research helps understand the biological basis of a rare neurodeve...
